Abaloparatide

Abaloparatide is a synthetic peptide modeled after the biologically active region of parathyroid hormone–related peptide (PTHrP 1–34). It interacts selectively with the parathyroid hormone type 1 receptor (PTH1R) expressed on osteoblasts, initiating intracellular signaling pathways that favor bone formation over resorption.

By activating adenylate cyclase and increasing cyclic adenosine monophosphate (cAMP) signaling, Abaloparatide stimulates osteoblast proliferation, differentiation, and extracellular matrix production while reducing osteoblast apoptosis. At the same time, it indirectly modulates osteoclast activity, allowing new bone formation to predominate within the remodeling cycle.

Through this mechanism, Abaloparatide has demonstrated the ability to increase bone mineral density, improve trabecular and cortical microarchitecture, and enhance overall skeletal strength in experimental and clinical research models. Ongoing investigations also explore its influence on cartilage metabolism, bone regeneration, and orthopedic repair processes.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

(Leder et al., 2015 — Journal of Bone and Mineral Research).